Meaningful Activity Intervention for Persons With Mild Cognitive Impairment

October 24, 2016 updated by: Indiana University

The purpose of this pilot study is to evaluate the feasibility of and satisfaction with the revised DEMA and to estimate effect sizes for DEMA through incorporation of a comparison group. Specific aims are as follows:

Aim 1: Evaluate feasibility of the study for MCI patient/caregivers. Aim 2: Estimate effect sizes for DEMA on MCI patient and caregiver outcomes. Aim 3: Evaluate MCI patients and family caregivers' satisfaction with and perceptions of DEMA or IS.

Study Overview

Detailed Description

Mild cognitive impairment (MCI) affects as many as 20% of older adults who are at a greater risk of developing Alzheimer's disease (AD). MCI involves functional decline that may include decrements in engagement in meaningful activities and one's own sense of confidence/mastery, and it is associated with depressive symptoms, poor satisfaction with family communication, and declining physical function. Existing interventions for MCI patients and caregivers often focus on a single problem, such as memory or physical activity and there are no available multi-faceted supportive care interventions to meet the needs of the MCI patients and their caregivers in order to prevent premature disengagement and risk for depressive symptoms. The Daily Enhancement of Meaningful Activity (DEMA) intervention uses a family dyadic, strengths-based, and positive health approach that builds on existing dyadic skills and values to accomplish meaningful activity engagement to address the priority needs for efficacious interventions to prevent premature disengagement and depressive symptoms in MCI patients. The DEMA builds on the investigators' previous descriptive work and gerontology theory, the model human occupation, and components of the Problem-Solving Therapy. The investigators' preliminary findings showed that the intervention and measures were acceptable, and suggestions were solicited from the participants for improving delivery. The purpose of this pilot study is to 1) evaluate the feasibility and satisfaction of the revised DEMA intervention; and 2) estimate effect sizes for the intervention through the incorporation of a comparison group. The MCI-caregiver dyads (n = 36 dyads) will be randomized to the DEMA or informational support groups; each group will receive 6 bi-weekly sessions (2 face-to-face and 4-phone delivered) with a trained intervener. The data from MCI patients and caregivers outcomes will be collected at pre-intervention, immediately (two weeks) post-intervention, and 3 months post-program evaluation. Descriptive statistics analysis will be used for satisfaction with and perception of the DEMA or informational support groups and general linear mixed models will be used to estimate the effect sizes of the intervention on the proximal and distal outcomes. Findings will inform the design of a subsequent R01 to: 1) test the efficacy of DEMA for MCI patient-caregiver dyads in a longitudinal randomized clinical trial; and 2) explore the costs/benefits of implementation. If it is found to be efficacious, DEMA has the potential to slow the rate of disability progression from MCI to AD and improve quality of life outcomes for patients and caregivers.

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana University School of Nursing

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 95 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

MCI patients:

  1. are aged 60 years or older,
  2. speak English,
  3. have both caregiver-reported, clinically significant decline in cognition and clinician-detected or research based cognitive impairment on the standardized health exam
  4. have at least one cognitive assessment score below the 7th percentile
  5. have a normal range in performance of daily living tasks based on informant interview information indicating that impairment does not rise to the level of dementia.

Family caregivers:

  1. are adults ≥ 21 years of age;
  2. have primary responsibility for providing unpaid care to an MCI relative, along with monitoring safety and providing social support
  3. are able to read and speak English
  4. are oriented to persons, places, and time [having a 6-item Mini-Mental State Examination (MMSE) score of 4 or above]

Exclusion Criteria:

MCI patients and family caregivers will be excluded if:

  1. the MCI patient or family caregiver has a diagnosed bipolar disorder or untreated schizophrenia;
  2. the family caregiver has significant cognitive impairment that may hinder participation (6-item MMSE < 4)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Daily Enhancement Meaningful Activity (DEMA)
The group member will receive Self-management Toolkit and 6 bi-weekly individualized sessions, 2 face-to-face and 4 via telephone delivered by a trained intervener. DEMA will provide autonomy support by helping patients to identify and prioritize activities, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed.
Active Comparator: Information Support (IS)
The IS group will receive 2 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer Association, educational brochure. Then they will receive 4 biweekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Patient_Depression symptoms: Patient Health Questionnaire Depression Scale (PHQ-9)
Time Frame: Change in depression from baseline to immediately (two-week)- and 3 months post-intervention
Change in depression from baseline to immediately (two-week)- and 3 months post-intervention

Secondary Outcome Measures

Outcome Measure
Time Frame
Patient_satisfaction with communication: The subscale of Communication and Affective Responsiveness
Time Frame: Change in satisfaction with communication from baseline to immediately (two-week)- and 3 months post-intervention
Change in satisfaction with communication from baseline to immediately (two-week)- and 3 months post-intervention
Patient_Physical Function: Alzheimer disease cooperative study activities of daily living inventory.
Time Frame: Change in physical function from baseline to immediately (two-week)- and 3 months post-intervention
Change in physical function from baseline to immediately (two-week)- and 3 months post-intervention
Patient_Life satisfaction : Life Satisfaction Index for the Third Age-Short Form
Time Frame: Change in life satisfaction from baseline to immediately (two-week)- and 3 months post-intervention
Change in life satisfaction from baseline to immediately (two-week)- and 3 months post-intervention
Patient_Satisfaction with program: Satisfaction with Meaningful Activity Program Scale is adapted from the Caregiver Satisfaction Scale
Time Frame: It will be collected at 3 months post-program evaluation
It will be collected at 3 months post-program evaluation
Patient_ Meaningful activities engagement performance and satisfaction: Canadian Occupational Performance Measure & weekly log
Time Frame: Change in meaningful activities engagement performance and satisfactionfrom baseline to immediately (two-weeks)- and 3 months post-intervention
Change in meaningful activities engagement performance and satisfactionfrom baseline to immediately (two-weeks)- and 3 months post-intervention
Patient_Sense of confidence: Confidence Scale
Time Frame: Change in sense of confidence from baseline to immediately (two-week)- and 3 months- post program
Change in sense of confidence from baseline to immediately (two-week)- and 3 months- post program
Caregiver_Depressive Symptoms: PHQ-9
Time Frame: Change in depressive symptoms from baseline to immediately (two-week)- and 3 months post-program evaluation
Change in depressive symptoms from baseline to immediately (two-week)- and 3 months post-program evaluation
Caregiver_ Caregiver life changes: Caregiving Outcomes Scale
Time Frame: Change in caregivign outcomes from baseline to immediately (two-week)- and 3 months post-post program
Change in caregivign outcomes from baseline to immediately (two-week)- and 3 months post-post program
Caregiver_- Satisfaction with program: Satisfaction with Meaningful Activity Program Scale is adapted from the Caregiver Satisfaction Scale
Time Frame: It will be assessed at 3 months post-program evaluation
It will be assessed at 3 months post-program evaluation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yvonne Lu, PhD, IU School of Nursing

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Actual)

March 1, 2015

Study Completion (Actual)

May 1, 2016

Study Registration Dates

First Submitted

April 26, 2013

First Submitted That Met QC Criteria

April 29, 2013

First Posted (Estimate)

April 30, 2013

Study Record Updates

Last Update Posted (Estimate)

October 25, 2016

Last Update Submitted That Met QC Criteria

October 24, 2016

Last Verified

October 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • 1R21NR013755-01 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild Cognitive Impairment

Clinical Trials on Daily Enhancement Meaningful Activity (DEMA)

Subscribe